Allison C. Ferguson

This study uses zebrafish to screen FDA-approved drugs for antithrombotic effects, identifying thyroid hormone and others as potential treatments for VTE subtypes.

This study shows that disrupting the kringle 1 domain of prothrombin in zebrafish causes late-onset mortality due to impaired clot formation, revealing its role in thrombin biosynthesis and activation.

The paper studies zebrafish factor V mutants to determine minimal hemostasis requirements and evaluates human F5 variants for their residual function.